share_log

Spero Therapeutics | 8-K: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

SEC ·  Mar 14 04:11
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.